EUVIMEDEUVIMED entdecken
Open Access

Nanobody activator improves sensitivity of the von Willebrand factor activity assay to multimer size

Qian Liang, Ernest T Parker, Gabrielle Dean, Matthew S Karpen, Yujia Wu, Xuefeng Wang, Jorge Di Paola, Cheryl L Maier, Shannon L Meeks, Pete Lollar, Robert F Sidonio, Renhao Li

Journal of Thrombosis and Haemostasis · 2024

DOI: 10.1016/j.jtha.2024.04.015 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Thrombosis and Haemostasis, 2024. Verfasst von Qian Liang und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Laboratory Medicine, Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China; Aflac Cancer and Blood Disorder…. Hauptthemen laut MEDLINE: von Willebrand Factor, Single-Domain Antibodies, Enzyme-Linked Immunosorbent Assay, Protein Multimerization. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NHLBI NIH HHS, National Heart Lung and Blood Institute, National Hemophilia Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: The activity of von Willebrand factor (VWF) in facilitating platelet adhesion and aggregation correlates with its multimer size. Traditional ristocetin-dependent functional assays lack sensitivity to multimer sizes. Recently, nanobodies targeting the autoinhibitory module and activating VWF were identified. OBJECTIVES: To develop an assay that can differentiate the platelet-binding activity of VWF multimers. METHODS: A novel enzyme-linked immunosorbent assay (nanobody-triggered glycoprotein Ib binding assay [VWF:GPIbNab]) utilizing a VWF-activating nanobody was developed. Recombinant VWF, plasma-derived VWF (pdVWF), and selected gel-filtrated fractions of pdVWF were evaluated for VWF antigen and activity levels. A linear regression model was developed to estimate the specific activity of VWF multimers. RESULTS: Of the 3 activating nanobodies tested, 6C11 with the lowest activation effect exhibited the highest sensitivity for high-molecular-weight multimers (HMWMs) of VWF. VWF:GPIbNab utilizing 6C11 (VWF:GPIbNab6C11) produced significantly higher activity/antigen ratios for recombinant VWF (>2.0) and HMWM-enriched pdVWF fractions (>2.0) than for pdVWF (∼1.0) or fractions enriched with shorter multimers ( 90% of the VWF activity measured by VWF:GPIbNab6C11 to that of HMWMs, which is significantly higher than all other activity assays tested. CONCLUSION: The VWF:GPIbNab6C11 assay exhibits higher sensitivity to HMWMs than ristocetin-based and collagen-binding assays. Future studies examining the application of this assay in clinical settings and any associated therapeutic benefit of doing so are warranted.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

von Willebrand FactorSingle-Domain AntibodiesEnzyme-Linked Immunosorbent AssayProtein MultimerizationHumansLinear ModelsRecombinant ProteinsBlood PlateletsPlatelet AggregationPlatelet Glycoprotein GPIb-IX ComplexProtein BindingPlatelet AdhesivenessMolecular Weight

Stichwörter der Autor:innen

nanobodyplateletristocetinsensitivityvon Willebrand factor

Substanzen

von Willebrand FactorSingle-Domain AntibodiesRecombinant ProteinsPlatelet Glycoprotein GPIb-IX Complex

Autor:innen und Institutionen

  • Department of Laboratory Medicine, Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China; Aflac Cancer and Blood Disorders Center, Children's Healthcare of Atlanta, Department of Pediatrics,…
  • Aflac Cancer and Blood Disorders Center, Children's Healthcare of Atlanta, Department of Pediatrics, Emory University School of Medicine, Atlanta, Georgia, USA.
  • Department of Statistics, School of Statistics and Center of Statistical Research, Southwestern University of Finance and Economics, Chengdu, China.
  • Department of Laboratory Medicine, Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China.
  • Department of Pediatrics, Washington University School of Medicine, St. Louis, Missouri, USA.
  • Department of Pathology and Laboratory Medicine, Emory University School of Medicine, Atlanta, Georgia, USA.

Förderung

  • NHLBI NIH HHS
  • National Heart Lung and Blood Institute
  • National Hemophilia Foundation
  • National Institutes of Health
  • China Scholarship Council
  • Hemophilia of Georgia
  • Shanghai Jiao Tong University Medical School Affiliated Ruijin Hospital
  • Children's Healthcare of Atlanta

Zitieren

APA

Liang, Q., Parker, E. T., Dean, G., Karpen, M. S., Wu, Y., Wang, X., Di Paola, J., Maier, C. L., Meeks, S. L., Lollar, P., Sidonio, R. F., & Li, R. (2024). Nanobody activator improves sensitivity of the von Willebrand factor activity assay to multimer size. Journal of Thrombosis and Haemostasis. https://doi.org/10.1016/j.jtha.2024.04.015

Vancouver

Liang Q, Parker ET, Dean G, Karpen MS, Wu Y, Wang X, et al. Nanobody activator improves sensitivity of the von Willebrand factor activity assay to multimer size. Journal of Thrombosis and Haemostasis. 2024. doi:10.1016/j.jtha.2024.04.015

BibTeX
@article{Liang2024,
  author = {Liang, Qian and Parker, Ernest T and Dean, Gabrielle and Karpen, Matthew S and Wu, Yujia and Wang, Xuefeng and Di Paola, Jorge and Maier, Cheryl L and Meeks, Shannon L and Lollar, Pete and Sidonio, Robert F and Li, Renhao},
  title = {Nanobody activator improves sensitivity of the von Willebrand factor activity assay to multimer size},
  journal = {Journal of Thrombosis and Haemostasis},
  year = {2024},
  doi = {10.1016/j.jtha.2024.04.015}
}
Kostenlos starten →